Erdafitinib Plus Cetrelimab Elicits Durable Responses in Metastatic Urothelial Carcinoma
Erdafitinib alone or in combination with cetrelimab has shown activity in a phase 2 trial of patients with FGFR-altered metastatic urothelial carcinoma.
Diagnosis & Disease Information
Pembrolizumab-Axitinib Improves Long-Term Outcomes vs Sunitinib in Advanced RCC
Combination pembrolizumab and axitinib continues to show superior efficacy to sunitinib in advanced clear cell renal cell carcinoma, according to updated data from a phase 3 trial.
Add-On Prostate Radiation Therapy for De Novo Low-Volume mCSPC Improves Outcomes
Prostate radiotherapy added to intensified systemic therapy for de novo low-volume mCSPC decreases the risk of radiographic disease progression.
Global Survey Suggests RCC Patients Are Underinformed, Face Obstacles to Care
Results of a global survey highlight areas for improvement in the care of patients with renal cell carcinoma.
Guidelines and Training Can Reduce Bladder Irrigation-Associated CAUTIs
An oral presentation at ONS Congress 2023 described an initiative to create a guideline to standardize IBI to prevent catheter-associated urinary tract infections in patients with urologic cancer.
Blood Type Associated With Immunotherapy Outcomes in RCC
Blood type may impact immunotherapy outcomes in patients with metastatic RCC, a study suggests.
Newly Identified Prostate Cancer Subtypes May Respond Differently to Treatment
Researchers say they have identified 4 subtypes of prostate cancer with distinct biological and clinical features, and these subtypes may respond differently to treatment.
Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid Tumors
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Associations Between Cancer and COVID-19 Death “More Substantial” in Women
The risk of in-hospital death from COVID-19 for patients with cancer differs by sex and cancer type, according to a new study.
ALLO-316, a CAR T-Cell Therapy, Shows Activity in Advanced RCC
ALLO-316 has shown activity in a phase 1 study of patients with heavily pretreated, advanced clear cell renal cell carcinoma.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...